Gapping up
In reaction to strong earnings/guidance/SSS: DRWI +11.1% (light volume), IGTE +8.4%, SYNA +0.8% (to pay ~$92.5 mln in cash and stock to acquire Validity Sensors; co sees Q1 revs of $220 mln vs $206.31 Capital IQ Consensus Estimate).
M&A news: PVR +17.5% (Regency Energy Partners to Acquire PVR Partners for $5.6 Billion), JOSB +0.9% (Men's Wearhouse adopts limited duration Shareholder Rights Plan; Jos. A. Bank responds to Mens Wearhouse (MW); will cont to pursue $48 per share proposal).
Select financial related names showing strength: ING +3.7%, PUK +3%, DB +2.4%, HBC +1.4%.
With sharp gain in futures, momentum stocks leading gains after showing relative strength amid recent selloff: TSLA +3.4% DDD +2.3% NFLX +2.6% ( initiated with a Buy at Needham), GRPN +2.3%, FB +2.2%, YELP +2%
Solar names moving higher: CSIQ +6.9%, JKS +6.3%, RSOL +4%, SOL +3.4%, STP +3%, YGE +3%, SPWR +2.8%, FSLR +1.2%
China internet names seeing upside move: YY +3.6%, DANG +3.1%, BIDU +1.2%
Other news: ACUR +29% (Acura Pharma announces settlement of Oxecta patent litigation with Par Pharmaceutical and Impax Laboratories), CHTP +9% ( announces FDA Advisory Committee to review NORTHERA), ACAD +6.7% (rebounding), ALU +5.4% (still checking), CLDX +4.6% (still checking), TTM +4.2% (still checking), DVAX +3.5% (initiates first human trial in asthma program), TEVA +3.2% (Teva Pharma announced steps to accelerate the reduction of costs and to optimize its structure and processes; $2.0 bln in annual cost savings by the end of 2017 including $1.0 bln by the end of 2014; reaffirms FY13 guidance), GILD +3.1% (Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia Early Because of Positive Risk-Benefit), DRYS +2.7% (still checking), MU +2.5% (still checking), TASR +1.8% (enters into a definitive agreement to acquire Familiar; team will be joining EVIDENCE.com), SIRI +1.8% (Sirius XM Radio announces its Board of Directors has approved an additional $2 bln common stock repurchase program), IMMU +1.8% (announces termination of agreement and return of worldwide rights to veltuzumab for all non-cancer indications), ARUN +1.6% (announces additional $100 mln share repurchase authorization), LMT +1.6% (Lockheed Martin and US Air Force are close to $2.2 bln satellites deal, according to reports), NUAN +1.4% (announced that it has signed an agreement to acquire Varolii), YHOO +1.2% (still checking), STX +0.7% (following reports SSNLF selling stake back to the company).
Analyst comments: ODP +5.3% (upgraded to Buy from Neutral at Janney ), SSYS +3.3% (upgraded to Overweight from Neutral at JP Morgan), TI +2.2% (upgraded to Sector Perform from Underperform at RBC Capital ), FCH +2% (upgraded to Buy from Neutral at Goldman), HPQ +1.8% (upgraded to Neutral from Underperform at Mizuho), DFS +1.4% (upgraded to Buy from Neutral at Citigroup), BA +0.5% (Boeing initiated with a Buy at Canaccord Genuity), CHKP +0.4% (Check Point upgraded to Outperform from Market Perform at Cowen)